Pfizer Stock Eyes Breakout On Call For $26 Billion In Covid Vaccine Sales

Pfizer said Tuesday it plans to seek full FDA approval for its Covid-19 vaccine by the end of the month. But Pfizer stock was just below a buy point despite strong earnings.
Read More